A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Overview

Información sobre este estudio

The purpose of this study is to evaluate the objective response rate (ORR) by RECIST 1.1 in subjects with TPS ≥ 1 percent.

The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Histologically or cytologically confirmed, newly diagnosed unresectable stage III or metastatic (M1a) intrathoracic NSCLC without EGFR sensitizing mutation or ALK translocation.
  • Age ≥ 22 years.
  • Have a PD-L1 positive (TPS ≥ 1%) tumor by local laboratory assessment.
  • Measurable disease by RECIST 1.1.
  • ECOG performance status of 0 to 1.
  • Have not received prior systemic treatments for NSCLC.
  • Life expectancy of at least 3 months.
  • Able to operate the NovoTTF-200T system.

Exclusion Criteria:

  • Has an extrathoracic metastasis (i.e., M component is M1b or M1c).
  • Has an EGFR sensitizing mutation and/ or ALK translocation.
  • If Stage III, can be treated with curative intent with either surgical resection and/or chemoradiation.
  • Has received prior systemic anti-cancer therapy or prior radiotherapy for NSCLC (palliative radiotherapy is allowed).
  • Being unable to operate the NovoTTF-200T device independently or with the help of a caregiver.
  • Pregnancy or breastfeeding.
  • Significant illnesses not associated with the primary disease.
  • Implanted electronic devices (e.g., pacemaker) in the upper torso.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated April 26, 2023. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Vinicius Ernani, M.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20524004

Mayo Clinic Footer